A major Phase 3 effort, the FIND-CKD trial, reported that finerenone—a non-steroidal mineralocorticoid receptor antagonist—slowed kidney function decline and reduced cardiovascular risk in adults with non-diabetic chronic kidney disease (CKD). The trial, described as the largest of its kind, directly evaluates kidney outcomes in a population that historically has had fewer disease-modifying options. The study’s results position finerenone as a potential core therapy beyond diabetes-associated CKD, with implications for labeling, reimbursement discussions, and guideline inclusion. For clinicians managing CKD patients without diabetes, the data provide a clearer evidence base for mineralocorticoid receptor pathway targeting. The report also underscores the ongoing shift in nephrology toward therapies validated on hard renal endpoints plus cardiovascular composites. If adopted broadly, that approach could reshape sequencing decisions for CKD care pathways.